*; George Suzuki, MD*; Walid Haddad, PhD; Yuval Mika, DSc; Elaine J. Tanhehco, PhD*; Victor G. Sharov, PhD*; Sidney Goldstein, MD*; Shlomo Ben-Haim, MD, PhD; Hani N. Sabbah, PhD*">
Journal Home
Search for

Volume 9, Issue 1, Pages 69-75 (February 2003)


View previous. 10 of 11 View next.

Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure☆☆

Hideaki Morita, MD*, George Suzuki, MD*, Walid Haddad, PhD, Yuval Mika, DSc, Elaine J. Tanhehco, PhD*, Victor G. Sharov, PhD*, Sidney Goldstein, MD*, Shlomo Ben-Haim, MD, PhD, Hani N. Sabbah, PhD*

Received 31 May 2002; received in revised form 6 November 2002 and 14 November 2002

Abstract 

Background: Nonexcitatory electrical, signals termed cardiac contractility modulation (CCM) have been shown to improve contractile force of isolated papillary muscles. In this study, we examined the effects of CCM signal delivery on left ventricular function in dogs with chronic heart failure (HF). Methods and Results: Chronic HF (ejection fraction ≤35%) was produced in 7 dogs by intracoronary microembolizations. The CCM signal was delivered during the absolute refractory period using a lead implanted in the anterior coronary vein. A right ventricular and an atrial lead were implanted and used for timing of the CCM signal delivery. Hemodynamic measurements were made at baseline and at 1, 2, 3, 4, 5, and 6 hours after initiating CCM signal delivery. Ejection fraction increased from 31 ± 1% at baseline to 41 ± 1% at 1 hour (P < .05), 42 ± 1% at 3 hours (P < .05), and 44 ± 2% at 6 hours (P < .05). Similarly, stroke volume increased from 26 ± 2 mL to 31 ± 3 mL at 1 hour (P < .05), 33 ± 3 mL at 3 hours (P < .05), and 34 ± 3 mL at 6 hours (P < .05). There were no significant changes compared to baseline in ejection fraction or stroke volume in 5 HF control dogs studied for up to 4 hours. Conclusion: In dogs with HF, CCM signal delivery for 6 hours elicited marked improvement in LV function. This novel approach may represent a useful adjunctive therapy for the treatment of patients with HF.

Detroit, Michigan

Mount Laurel, New Jersey

From the *Departments of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, Michigan; and Impulse Dynamics, Mount Laurel, New Jersey

 Doctors Haddad, Mika, and Ben-Haim are employees/officers of Impulse Dynamics, the manufacturer of this technology.

☆☆ Supported, in part, by grants from Impulse Dynamics and the National Heart, Lung, and Blood Institute, HL49090-07.

 Reprint requests: Hani N. Sabbah, PhD, Director, Cardiovascular Research, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202.

PII: S1071-9164(02)25408-1

doi:10.1054/jcaf.2003.8


View previous. 10 of 11 View next.